Comparison between SGLT2 inhibitors and DPP4 inhibitors.
While all SGLT2 inhibitors exerted comparable effects in reducing hyperglycemia, improvement of these diabetes-related diseases and complications was more potent with the two long-acting drugs (ipragliflozin and dapagliflozin) than with the four intermediate-acting four drugs (tofogliflozin, canagliflozin, empagliflozin, and luseogliflozin), albeit without statistical significance.
SGLT2 inhibitors are a novel class of antidiabetic agents that have demonstrated positive efficacy and safety outcomes in the setting of chronic HF. The FDA’s recent approval of dapagliflozin for reducing HHF may pave the way for other SGLT2 inhibitors to follow suit.
The SGLT2 inhibitor drugs include canagliflozin, dapagliflozin, empagliflozin, ipragliflozin, and tofogliflozin; however, only canagliflozin, dapagliflozin, and empagliflozin have been approved by the US Food and Drug Administration (FDA). These pharmaceuticals promote glycosuria via the kidneys and enhance sugar excretion from the body.
The SGLT2 inhibitor was associated with a significant increase in HDL-C and LDL-C after 24 weeks of SGLT2 inhibitor treatment in patients with type 2 diabetes compared with those with DPP-4 inhibitor treatment in this study.
A team studied four research papers which had assessed how three SGLT2 inhibitors (empagliflozin, canagliflozin and dapagliflozin) impacted kidney disease risk among individuals with type 2 diabetes. The team gathered evidence from 4 trials and completed a systematic review and meta-analysis to document the impact SGLT2 inhibitors had on the occurrence of kidney failure in type 2 diabetes.
Background: Both sodium glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) inhibitors can be used to treat patients with type 2 diabetes mellitus (T2DM) that is inadequately controlled with insulin therapy, and yet there has been no direct comparison of these two inhibitors. Methods: We searched MEDLINE, EMBASE, LILACS, the Cochrane Central Register of Controlled.
SGLT2 inhibitors may increase urination and raise the risk of female yeast infections and urinary tract infections. These drugs can also lead to low blood pressure. Kidney function needs to be tested before and during treatment with SGLT2 inhibitors; Persons with severe kidney disease or on dialysis are not recommended to be on this medicine; New evidence suggests that SGLT2 inhibitors might.
To do our study, we will compare SGLT2 inhibitors with another class of drug that has been around for a longer called 'dipeptidyl peptidase-4' (DPP-4) inhibitors. We will compare effectiveness and safety outcomes between the groups and we will also carry out a sub-analysis focusing on comparing empagliflozin-drug with DPP-4 inhibitors. We will make use of four large primary care databases in.
Background: SGLT2-inhibitors are potent antihyperglycemic drugs for patients with type 2 diabetes and have been shown to reduce body weight. However, it is unclear which body compartments are reduced and to what extent. Methods: In this longitudinal observational study, we analyzed the body composition of 27 outpatients with type 2 diabetes mellitus during the first week and up to 6 months.
Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of kidney complications in people with type 2 diabetes, researchers conclude in a new study. SGLT2 inhibitors are a class of drug that includes the medications; dapagliflozin, canagliflozin and empagliflozin. They work by reducing the amount of glucose that is reabsorbed into the blood within the kidneys.
The sodium-glucose cotransporter (SGLT) 2 offer a novel approach to treating type 2 diabetes by reducing hyperglycaemia via increased urinary glucose excretion. In the present study, the pharmacokinetic, pharmacodynamic, and pharmacologic properties of all six SGLT2 inhibitors commercially available in Japan were investigated and compared.
Among them, 14 with IC 50: 0.64 n m emerged as the most potent SGLT2 inhibitor with the best selectivity for inhibition of SGLT2 (IC 50:0.64 n m ) over SGLT1 (IC 50: 500 n m ) as compare to Dapagliflozin. On the other hand, compound 15a exhibited moderate selectivity for inhibition of SGLT2 (IC 50: 4.94 n m ) over SGLT1 (IC 50: 68.46 n m ).
Antonios Douros, M.D., Ph.D., from McGill University in Montreal, and colleagues matched 208,757 new users of SGLT-2 inhibitors with 208,757 recipients of dipeptidyl peptidase-4 (DPP-4) inhibitors to compare the risk for DKA in patients with type 2 diabetes. Data were obtained from seven Canadian provinces and the United Kingdom.
All FDA-approved SGLT2 inhibitors (SGLT2i) are currently available in two doses. While most SGLT2i have demonstrated CV benefit, there may be a difference in hemoglobin A1c (A1c) reduction between both doses. We performed a meta-analysis to evaluate the efficacy of both SGLT2i doses compared to maximum DPP-4 inhibitor (DPP-4i) dose.
The sodium-glucose linked transporter-2 (SGLT2) inhibitors, targeted to improve glycaemic control by attenuating renal glucose re-uptake, are emerging to be one of the most impactful cardiovascular drug classes of recent times.
In contrast, SGLT2 inhibitors reduced the relative risk of hospitalization for heart failure (HHF) by 31%, whereas there was only a non-significant 7% relative risk reduction with GLP1-RA.